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INTRODUCTION
Treatment of depression with currently available antide-
pressants is not satisfied, because only 30–40% of real-life pa-
tients with major depressive disorder reach a remission with 
the first selected antidepressant.1 Therefore, it is important to 
develop new strategies to increase remission rates and to short-
en the time to remission. Prediction of response to antidepres-
sants at early period after starting the antidepressant is neces-
sary to decide continuing the antidepressant, changing other 
one, or augmentation strategy. A substantial body of evidence 
from many retrospective studies shows that non-improve-
ment, often defined as <20% reduction of depressive symp-
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toms assessed with a routine scale like the Hamilton Rating 
Scale for Depression (HAMD)2 after 14 days of treatment is a 
highly specific marker for final treatment failure with an un-
changed treatment.3
Brain-derived neurotrophic factor (BDNF) plays an impor-
tant role in the pathophysiology of depression.4,5 In addition, 
blood (serum or plasma) levels of BDNF is a biomarker for de-
pressive state.6-9 We previously reported that baseline serum 
BDNF levels predict subsequent response to mirtazapine in 
Japanese patients with major depressive disorder.10 In another 
study, we demonstrated that baseline serum BDNF levels did 
not significantly different between responder and non-re-
sponders to selective serotonin reuptake inhibitor (SSRI) or 
serotonin noradrenaline reuptake inhibitor medications.11,12 
Wolkowitz et al.13 reported that pre-treatment serum BDNF 
levels were significantly higher in the responders than in the 
non-responders. From these findings into account, it is con-
troversial baseline serum BDNF levels could predict later re-
sponse to treatment with antidepressants. Recently, Tadic et 
al.14 reported that the non-increase of serum BDNF level and 
the non-improvement of HAMD from baseline to day 7 or 14 
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predicted later non-response and non-remission with mod-
erate to high specificity. In clinical practice, prediction for re-
sponse to antidepressants within an early point is an important 
issue. Therefore, we hypothesized that serum levels 4 weeks 
after starting SSRIs could predict subsequent response to SS-
RIs, it could help to decide in changing other antidepressants, 
increase the same antidepressant, or choosing augmentation 
strategy. 
We consider that if changes in serum BDNF levels at early 
point predict the subsequent outcome of the response to SS-
RIs, the changes in serum BDNF levels might become useful 
tool for predictions for SSRIs response. To confirm the hy-
pothesis, we examined the relation between serum BDNF lev-
els at 4 weeks and subsequent clinical response to SSRIs.
 
METHODS
This study included 150 in- or outpatients in our university 
hospital who met the DSM-IV-TR criteria15 for major depres-
sive disorder without psychotic features and who scored at 
least 16 on the 17-items of the Hamilton Raring Scale for De-
pression (HAMD-17). Fifty-one patients were male and 99 
were female. The age of the subjects ranged from 22 to 76 
years (mean±SD=50.4±15.1). None had received any antide-
pressant drugs or mood stabilizers at least two weeks prior to 
the study. All patients were physically healthy and no subjects 
had a history of alcohol and/or drug abuse. None had co-mor-
bid any anxiety disorders and personality disorders. The pa-
tients were treated with paroxetine, sertraline, or fluvoxamine. 
There were 60 cases treated with paroxetine, 72 cases treated 
with sertraline, and 28 cases treated with fluvoxamine. Initial 
dose of paroxetine, sertraline, or fluvoxamine were 10 mg/day, 
25 mg/day, or 25 mg/day, respectively, and the dose was in-
creased until the patients tolerated adverse effects (the dose 
was not fixed). Maximum dose of paroxetine, sertraline or flu-
voxamine were 40 mg/day, 100 mg/day, or 150 mg/day, re-
spectively. The average dose of each antidepressant was as fol-
lows; paroxetine: 30.5±12.4 mg/day, sertraline: 76.7±24.0 mg/
day, fluvoxamine: 100±26.3 mg/day. We evaluated the sever-
ity of depressive state using the HAMD-17 before (T0) and 4 
(T4) and 8 weeks (T8) after treatment with paroxetine, sertra-
line, or fluvoxamine. We defined the patients whose scores of 
the HAMD-17 decreased 50% or more as responders, where-
as, below 50% as nonresponders.
All blood samples were taken at 7:00 am before breakfast (at 
least 12 hours after the last medication) before (T0) and 4 (T4) 
and 8 weeks (T8) after treatment with paroxetine, sertraline, 
or fluvoxamine. Fifteen milliliters of venous blood was drawn 
with the patient in the supine position, after the patient had 
been lying at rest overnight. The serum samples were quickly 
separated in a centrifuge (2000 g, 10 min, 4°C) and stored at 
-80°C until assay. The serum BDNF levels were measured us-
ing a BDNF Emax Immunoassay Kit (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. In short, 
96-well microplates were coated with anti-BDNF monoclonal 
antibody and incubated at 4°C for 18 hours. The plates were 
incubated in a blocking buffer for 1 hour at room temperature. 
The samples diluted with assay buffer by 100-times and BDNF 
standards were kept at room temperature under conditions of 
horizontal shaking for 2 hours, followed by washing with the 
appropriate washing buffer. The plates were incubated with 
antihuman BDNF polyclonal antibody at room temperature 
for 2 hours and washed with the washing buffer. The plates 
were then incubated with anti-IgY antibody conjugated to 
horseradish peroxidase for 1 hour at room temperature, and 
incubated in peroxidase substrate and tetramethylbenzidine 
solution to induce a color reaction. The reaction was stopped 
with 1 mol/L hydrochloric acid. The absorbance at 450 nm was 
measured with an Emax automated microplate reader. Mea-
surements were performed in duplicates. The standard curve 
was linear from 5 pg/mL to 5000 pg/mL, and the detection 
limit was 10 pg/mL. Cross-reactivity to related neurotrophins 
(NT-3, NT-4, NGF) was less than 3%. Intra- and interassay 
coefficients of variation were about 5% and 7%, respectively. 
The recovery rate of the exogenous added BDNF in the mea-
sured plasma samples was more than 95%.
Actually, we examined the change of serum BDNF levels in 
same samples in a same day at time 8:00, 12:00, 16:00, 20:00, 
24:00, and no significant changes in serum BDNF were ob-
served within a day (data not shown). This study was ap-
proved by the ethics committee of the University of Occupa-
tional and Environmental Health, and written informed con-
sent was obtained from all participants.
Statistical analysis
The logistic regression analysis was performed for the re-
sponse to SSRIs at T4 as a dependent variable and changes in 
BDNF, sex, age, dose of SSRIs at T8, and HAMD-17 at T0 as 
independent variables. The area under the curve (ROC-AUC) 
was made for the prediction of the response at T8 with using 
a BDNF change from T0 to T4. We used the repeated measures 
of ANOVA comparing HAMD-17 scores and serum BDNF 
levels at each point. Significance was set at <0.05. All analyses 
were done using the Japanese version of SPSS v15.1 (SPSS, To-
kyo, Japan).
RESULTS
Among 150 patients, 70 (46.3%) were responders to treat 
of SSRIs at week 8, and the rest (53.3%) were nonresponders. 
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Any independent variables (changes in BDNF, sex, age, dose 
of SSRIs, and HAMD-17 at T0) were not associated with the 
response at T8 (Table 1). The AUC of a BDNF change from T0 
to T4 was 0.54 for the response to at T8 (p=0.311, 95% confi-
dence interval=0.137–0.681) (Figure 1). Significantly positive 
correlations were not observed between the changes in HA-
MD-17 (T0–8) or (T0–4) and the changes in BDNF (T8–T0) 
or (T4–T0) (r=0.005, p=0.524) (r=0.170, p=0.9107) (Figures 2 
and 3). The scores of HAMD-17 significantly decreased from 
at T0 (21.0±4.3) to at T4 (13.8±4.9) and at T8 (10.0±5.6) (p< 
0.0001) (Figure 4). The serum BDNF levels significantly in-
creased from at T0 (8.6±7.2 ng/mL) to at T8 (11.2±8.4 ng/mL), 
but not at T4 (9.2±6.1 ng/mL) (p=0.018) (Figure 5).
Table 1. Independent factors regarding response to SSRIs
Dependent variable Independent variable Wald chi-square p Adjusted R2
Change in BDNF (T4–T0)/T0 0.522 0.470
Sex 0.727 0.394
Responder/Nonresponder Age 0.125 0.724 0.0218
Dose of SSRIs at T8 0.018 0.893
HAMD-17 at T0 0.254 0.614
SSRIs: Selective Serotonin Reuptake Inhibitors, BDNF: brain-derived neurotrophic factor, HAMD-17: 17-items of the Hamilton Rating Scale 
for Depression
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Figure 1. The ROC analysis of BDNF change from T0 to T4 for the 
response at T8. ROC: receiver operating characteristic, BDNF: 
brain-derived neurotrophic factor, T0: before staring SSRIs, T4: 4 
weeks after SSRIs, T8: 8 weeks after SSRIs, SSRIs: Selective Se-
rotonin Reuptake Inhibitors.
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Figure 2. The changes in HAMD-17 (T0‒4) and the changes in BDNF 
(T4‒0). HAMD-17: Total scores in 17-items of Hamilton Rating 
Scale for Depression, T0: before staring SSRIs, T4: 4 weeks after 
SSRIs, SSRIs: Selective Serotonin Reuptake Inhibitors.
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Figure 3. The changes in HAMD-17 (T0‒8) and the changes in BDNF 
(T8‒0). HAMD-17: Total scores in 17-items of Hamilton Rating Scale 
for Depression, T0: before staring SSRIs, T8: 8 weeks after SSRIs, 
SSRIs: Selective Serotonin Reuptake Inhibitors.
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Figure 4. The changes in HAMD-17 at T0, T4, and T8. *p<0.0001. 
HAMD-17: Total scores in 17-items of Hamilton Rating Scale for 
Depression, T0: before staring SSRIs, T4: 4 weeks after SSRIs, T8: 
8 weeks after SSRIs, SSRIs: Selective Serotonin Reuptake Inhibitors.
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DISCUSSION
Treatment with SSRIs for 4 or 8 weeks significantly decreased 
the HAMD-17 scores in patients with MDD, and also increased 
serum BDNF levels at T8, but not at T4 (Figures 4 and 5).
In the present study, we demonstrated that changes in se-
rum BDNF, sex, age, dose of SSRIs, and HAMD17 at baseline 
were not associated with the clinical response to SSRIs at day 
28. The results in the present study revealed that the changes 
in serum BDNF and the HAMD-17 were both independent of 
the clinical outcome. Tadic et al.14 reported that the individual 
marker early serum BDNF non-increase has a positive predic-
tive value for final treatment failure. In addition, Dreimuller 
et al.16 reported the changes in plasma BDNF at day 7 com-
bined with HAMD improvement might be a predictor for 
good response to antidepressants. The between in the present 
study and those recent studies remain unknown. The early ch-
anges in BDNF only could not predict subsequently response 
to SSRIs. In other word, it might be necessary to combine the 
changes in HAMD scores. To the best of our knowledge, there 
have been at least four meta-analyses of studies of blood 
BDNF levels in depressed patients.6-9 The results of previous 
investigations have generally revealed that blood BDNF levels 
in depressed patients are significantly lower than those of he-
althy subjects. Taken together, these findings suggest that 
blood BDNF levels are a candidate biomarker for depression. 
However, it seems difficult to predict subsequent responses to 
SSRIs at early point of serum BDNF levels only. Actually, we 
previously reported that serum BDNF levels were not changed 
at all at T4, and were for the first time increased at T8. The re-
sults in the present study were not contradicted to our previ-
ous results in our previous study.11 In short, it takes at least 8 
weeks or more to change the serum BDNF levels in patients 
with response to SSRIs. Furthermore, the AUC value in the 
present study was 0.54, and the ROC was almost linear sug-
gesting the prediction for response to SSRIs using the changes 
in serum BDNF levels (T0–T4)/T0 is low and not useful 
(Figure 1). This result was not contradicted with the results 
that no correlations were found the changes in HAMD (T0–4) 
or (T0–8) and the changes in BDNF (T4–0) or BDNF (T8–0).
There are several limitations in the present study. The source 
of circulating BDNF remains unknown. Platelets, brain, and 
vascular endothelial cells are considered candidate sources. 
BDNF assessed in serum represented the portion of BDNF 
stored in platelets, which bind, store, and release BDNF upon 
activation by a number factors, including physiological stress 
and injuries. But, even with agonist stimulation only about half 
of the BDNF in platelets is secreted, which suggests that plate-
lets maintain a stable pool of BDNF, a buffer system.17 Previ-
ously, it was reported that BDNF levels in the brain and serum 
underwent similar changes during maturation and aging pro-
cess in rats,18 indicating that plasma BDNF levels might in part 
reflect the BDNF in the brain. In contrast to this, Radka et al.19 
reported that the BDNF detected in human serum was de-
rived from platelet degranulation, and that circulating levels 
of BDNF are negligible. Furthermore, the plasma assay mea-
sures BDNF released in the blood, which is quite unstable. 
Plasma BDNF, for example, has very low retest stability when 
measured twice within one year, and there are substantial ch-
anges even during one day. Such variation is one drawback to 
assessing BDNF in plasma and may help explain the lack of 
association with measures of depression. Previous studies have 
also reported that a large degree of dispersion, which suggests 
that it is a problematic feature of the plasma BDNF measure-
ment. A recent study also raises methodological concerns re-
garding the assessment of BDNF in plasma and recommends 
measuring BDNF in serum.17 From these findings into ac-
count, it is not clear as to what extent peripheral BDNF reflects 
central BDNF. Since it is well established that platelets are the 
major source of peripheral BDNF,17,21 it would be nice to have 
the BDNF data presented also in the framework of platelet 
counts of the investigated subjects. Furthermore, there is in-
creasing evidence that sampling characteristics, several so-
ciodemographic variables (such as urbanicity, age, sex), life-
style factors (such as smoking status and food and alcohol 
intake), somatic diseases and even self-reported depressive 
symptoms are relevant determinants of peripheral BDNF lev-
els.17-19 Thus, it is mandatory that the results presented are dis-
cussed with respect to these determinants. Therefore, further 
precise and well-controlled study considering above problems 
should be done to lead to robust results.
In conclusion, the changes in only serum BDNF levels from 
T0 to T4 could not predict the subsequent responses to SSRIs 
at T8. 
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Figure 5. The changes in serum BDNF at T0, T4, and T8. *p<0.05. 
BDNF: brain-derived neurotrophic factor, T0: before staring SS-
RIs, T4: 4 weeks after SSRIs, T8: 8 weeks after SSRIs, SSRIs: 
Selective Serotonin Reuptake Inhibitors.
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